S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
NASDAQ:NVCR

NovoCure (NVCR) Stock Price, News & Analysis

$14.64
+1.57 (+12.01%)
(As of 03/27/2024 ET)
Today's Range
$12.92
$15.49
50-Day Range
$12.42
$17.29
52-Week Range
$10.87
$83.60
Volume
11.93 million shs
Average Volume
1.00 million shs
Market Capitalization
$1.57 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$33.88

NovoCure MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
133.1% Upside
$34.13 Price Target
Short Interest
Bearish
5.75% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.15
Upright™ Environmental Score
News Sentiment
0.43mentions of NovoCure in the last 14 days
Based on 21 Articles This Week
Insider Trading
Selling Shares
$127,161 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.73) to ($1.79) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.87 out of 5 stars

Medical Sector

239th out of 939 stocks

Surgical & Medical Instruments Industry

29th out of 96 stocks

NVCR stock logo

About NovoCure Stock (NASDAQ:NVCR)

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

NVCR Stock Price History

NVCR Stock News Headlines

NovoCure (NASDAQ:NVCR) Receives Neutral Rating from Wedbush
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
NovoCure: Sell The METIS-Inspired Rally
Peeling Back The Layers: Exploring NovoCure Through Analyst Insights
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Novocure Shares Rise After Phase 3 METIS Trial Met Primary Endpoint
NovoCure (NASDAQ:NVCR) Stock Price Down 6%
NVCR Dec 2025 17.500 call
NVCR Jan 2026 20.000 call
NVCR Apr 2024 10.000 put
NVCR Apr 2024 17.500 call
See More Headlines
Receive NVCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NovoCure and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/22/2024
Today
3/27/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:NVCR
Fax
N/A
Employees
1,453
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$34.13
High Stock Price Target
$51.00
Low Stock Price Target
$15.00
Potential Upside/Downside
+131.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
9 Analysts

Profitability

Net Income
$-207,040,000.00
Pretax Margin
-37.65%

Debt

Sales & Book Value

Annual Sales
$509.34 million
Book Value
$3.39 per share

Miscellaneous

Free Float
101,021,000
Market Cap
$1.57 billion
Optionable
Optionable
Beta
0.41
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

NVCR Stock Analysis - Frequently Asked Questions

Should I buy or sell NovoCure stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NovoCure in the last twelve months. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NVCR shares.
View NVCR analyst ratings
or view top-rated stocks.

What is NovoCure's stock price target for 2024?

9 analysts have issued 1 year price targets for NovoCure's stock. Their NVCR share price targets range from $15.00 to $51.00. On average, they anticipate the company's stock price to reach $34.13 in the next twelve months. This suggests a possible upside of 133.1% from the stock's current price.
View analysts price targets for NVCR
or view top-rated stocks among Wall Street analysts.

How have NVCR shares performed in 2024?

NovoCure's stock was trading at $14.93 on January 1st, 2024. Since then, NVCR shares have decreased by 1.9% and is now trading at $14.64.
View the best growth stocks for 2024 here
.

When is NovoCure's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our NVCR earnings forecast
.

How were NovoCure's earnings last quarter?

NovoCure Limited (NASDAQ:NVCR) announced its quarterly earnings data on Thursday, February, 22nd. The medical equipment provider reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.08. The medical equipment provider had revenue of $133.80 million for the quarter, compared to the consensus estimate of $133.80 million. NovoCure had a negative net margin of 40.65% and a negative trailing twelve-month return on equity of 51.63%. NovoCure's revenue was up 4.2% on a year-over-year basis. During the same period in the previous year, the business earned ($0.36) EPS.

What guidance has NovoCure issued on next quarter's earnings?

NovoCure updated its fourth quarter 2023 earnings guidance on Monday, January, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $133.8 million-$133.8 million, compared to the consensus revenue estimate of $129.3 million.

What is Asaf Danziger's approval rating as NovoCure's CEO?

17 employees have rated NovoCure Chief Executive Officer Asaf Danziger on Glassdoor.com. Asaf Danziger has an approval rating of 90% among the company's employees.

What other stocks do shareholders of NovoCure own?
Who are NovoCure's major shareholders?

NovoCure's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.13%), Vanguard Group Inc. (9.11%), Capital International Investors (8.29%), Baillie Gifford & Co. (4.53%), Capital World Investors (3.07%) and Price T Rowe Associates Inc. MD (2.11%). Insiders that own company stock include Asaf Danziger, Ashley Cordova, Ely Benaim, Frank X Leonard, Frank X Leonard, Gabriel Leung, Jeryl L Hilleman, Martin J Madden, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen and William F Doyle.
View institutional ownership trends
.

How do I buy shares of NovoCure?

Shares of NVCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NVCR) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners